Gefitinib + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Sep 1, 2008 → Feb 1, 2011
NCT ID
NCT00770588About Gefitinib + Placebo
Gefitinib + Placebo is a approved stage product being developed by AstraZeneca for Non-small Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT00770588. Target conditions include Non-small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00770588 | Approved | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)